Medtronic launches MiniMed Go Smart MDI system across EMEA for ages 2–6 and 7+
Medtronic launched the MiniMed Go Smart MDI system with Simplera sensor across Europe, integrating InPen smart insulin pen data into one mobile app. The system, approved for insulin-requiring patients aged 7 and older (and ages 2–6 under supervision), delivers real-time dose alerts, a calculator and continuous guidance.
1. EMEA Commercial Rollout
Medtronic has begun a phased commercial launch of the MiniMed Go Smart MDI system with Simplera sensor across Europe starting this month, making the solution available to healthcare providers and patients in key EMEA markets.
2. Integrated Smart MDI System Features
The system unifies InPen smart insulin pen dose data and continuous glucose readings from the Simplera sensor into a single mobile app, offering built-in dose calculations, real-time missed-dose alerts and personalized guidance for multiple daily injections.
3. Clinical Data on Missed Dose Alerts
Research indicates skipping two weekly bolus doses may raise HbA1C by up to 0.4, and missing four bolus doses over 14 days can cut Time in Range by over 5%. Real-world use of the prior Smart MDI system showed users responding to more than 75% of missed-dose alerts achieved 67.2% Time in Range versus 55.7% cohort average, and up to 71.5% when addressing high blood sugar alerts.
4. Regulatory Approvals and Sensor Compatibility
In Europe, the MiniMed Go system is CE-marked for insulin-requiring patients aged 7 and older, and for ages 2–6 under adult supervision. Compatibility with Abbott’s Instinct Go sensor is pending CE approval, offering 7- or 15-day sensor options once cleared.